100余项中国研究入选2025 ELCC，哪些研究可能成为肺癌诊疗的新风向？

Amivantamab Plus Lazertinib vs Osimertinib in First-line (1L) EGFR-mutant (EGFRm) Advanced NSCLC: Final Overall Survival (OS) from the Phase 3 MARIPOSA Study

埃万妥单抗联合兰泽替尼对比奥希替尼一线治疗EGFR突变晚期NSCLC患者：3期MARIPOSA 研究最终总生存期（OS）结果

汇报人：杨志新（中国台湾台北）

Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for advanced squamous non-small-cell lung cancer (sqNSCLC): 5y update from the phase 3 CameL-sq trial

卡瑞利珠单抗联合化疗（Cam-chemo）作为晚期鳞状非小细胞肺癌（sqNSCLC）的一线（1 L）治疗：III期CameL-sq试验的5年更新

汇报人：周彩存（上海市东方医院）

Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: a single-arm, phase 2 trial

一线化疗免疫治疗后寡残留NSCLC的巩固立体定向放疗：单臂II期试验

汇报人：Hongru Chen (上海)

Subgroup Analysis of First-Line Camrelizumab Plus Chemotherapy in Brain Metastases of NSCLC: Results from the CTONG 2003 Trial

卡瑞珠单抗+化疗一线治疗NSCLC脑转移的亚组分析：CTONG 2003试验结果

汇报人：黎扬斯（广东省人民医院肺癌研究所）

Durvalumab with or without tremelimumab plus chemotherapy as first-line treatment for metastatic NSCLC: Results from the phase 3 POSEIDON extended China cohort

度伐利尤单抗联合或不联合tremelimumab联合化疗作为转移性NSCLC的一线治疗：3期POSEIDON扩展中国队列的结果

汇报人：王洁 (中国医学科学院肿瘤医院)

Clinical Characteristics and Survival Outcomes of Long-Term Responders for advanced Non-Small Cell Lung Cancer Patients with First-line PD-1/PD-L1 Inhibitors: A Multicenter Retrospective Study

接受一线PD-1/PD-L1抑制剂治疗的晚期NSCLC患者长期应答者的临床特征和生存结局：一项多中心回顾性研究

汇报人：Zhijuan Du（北京）

Camrelizumab Plus Chemotherapy as First-Line Treatment for Advanced Non-squamous NSCLC with Brain Metastases: Final overall survival results from the CAP-BRAIN trial

卡瑞利珠单抗+化疗作为晚期非鳞状NSCLC伴脑转移的一线治疗：CAP-BRAIN试验的最终总生存结果

汇报人：侯雪 (中山大学肿瘤防治中心)

Polymeric micelles paclitaxel (pm-Pac), carboplatin combined with sintilimab in the first-line treatment of advanced non-squamous non-small cell lung cancer(nsq-NSCLC): Phase II study

聚合物胶束紫杉醇（pm-Pac）、卡铂联合信迪利单抗一线治疗晚期非鳞状非小细胞肺癌（nsq-NSCLC）：II期研究

汇报人：周云 (江苏省肿瘤医院)

Clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: a systematic review and meta-analysis

癌症疫苗在晚期NSCLC患者一线治疗后的临床和安全性结局：一项系统性综述和荟萃分析

汇报人：Shaoyi Chen (北京)

Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-NSCLC): programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase 3 RATIONALE-304 trial

替雷利珠单抗（TIS）联合化疗（CT）作为局部晚期或转移性非鳞状非小细胞肺癌（LA/M nsq-NSCLC）的一线（1 L）治疗：随机化、III期RATIONALE-304试验的程序性死亡配体1（PD-L1）表达≥50%亚组分析

汇报人：于雁 (哈尔滨医科大学附属肿瘤医院)

Real World Efficacy and Safety of Anlotinib in NSCLC Previously Treated with Immune Checkpoint Inhibitors
安罗替尼在既往接受过免疫检查点抑制剂治疗的NSCLC中的真实世界疗效和安全性

汇报人：董宇超 (上海长海医院)

Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective stud

比较卡瑞利珠单抗、帕博利珠单抗、替雷利珠单抗和信迪利单抗一线治疗NSCLC患者：一项回顾性研究

汇报人：于韶荣 (江苏省肿瘤医院)

Efficacy and safety of cadonilimab-based therapies in non-small cell lung cancer patients with progression after immunotherapy

卡度尼利单抗治疗免疫治疗后进展的NSCLC患者的疗效和安全性

汇报人：于韶荣 (江苏省肿瘤医院)

The impact of prior bevacizumab on the efficacy of anlotinib in advanced non-squamous non-small cell lung cancer
既往接受过贝伐单抗治疗对安罗替尼治疗晚期非鳞状NSCLC疗效的影响

汇报人：Jiale Wang (上海)

Efficacy and Safety of Firmonertinib 160mg Combined with Intrathecal Injection Pemetrexed in NSCLC Patients with EGFR Mutations and Leptomeningeal Metastases

伏美替尼160 mg联合鞘内注射培美曲塞治疗EGFR突变伴软脑膜转移的NSCLC患者的疗效和安全性

汇报人：李晓燕 (首都医科大学附属北京天坛医院)

Clinical value and optimal timing of cranial stereotactic radiotherapy for third-generation EGFR-TKI-treated NSCLC with baseline limited brain metastases

颅内立体定向放射治疗经第三代EGFR-TKI治疗的基线局限性脑转移NSCLC的临床价值和最佳时机

汇报人：Silai Yu (上海)

Safety and Efficacy of Aumolertinib Treatment in Patients with advanced NSCLC Harboring 20ins and uncommon EGFR Mutations (AIM)

阿美替尼治疗携带EGFR 20ins和罕见EGFR突变的晚期NSCLC患者的安全性和疗效（AIM）

汇报人：方文峰 (中山大学附属肿瘤医院)

Response to first-line osimertinib plus pemetrexed/carboplatin in EGFR-mutant advanced NSLCLC with high PD-L1 expression

EGFR突变晚期NSLCLC伴PD-L1高表达患者对一线奥希替尼联合培美曲塞/卡铂的应答情况

汇报人：Chengdi Weng (广州)

Firmonertinib (formerly furmonertinib) combined with anlotinib in patients with treatment-naive EGFR-mutant non-small-cell lung cancer: updated results from FOCUS-A study
伏美替尼联合安罗替尼治疗未经治疗的EGFR突变NSCLC患者：FOCUS-A研究的更新结果

汇报人：韩宝惠（上海交通大学医学院附属胸科医院）

A real-world study of furmonertinib in uncommon EGFR mutated non-small cell lung cancer with central nervous system metastasis
伏美替尼治疗罕见EGFR突变NSCLC伴中枢神经系统转移的真实世界研究

汇报人：方申存 (南京市胸科医院)

Long-term Follow-up of Limertinib (ASK120067) in Patients with Locally Advanced or Metastatic EGFR T790M NSCLC: A multicentre, single-arm, phase 2b study
利厄替尼（ASK120067）在局部晚期或转移性EGFR T790M NSCLC患者中的长期随访：一项多中心、单臂、IIb期研究

汇报人：邬麟（湖南省肿瘤医院）

A Phase II Study of Sunvozertinib Combined with Anlotinib in EGFR-TKIs resistant EGFRm Advanced NSCLC Patients（WU-KONG9）
舒沃替尼联合安罗替尼治疗EGFR-TKI耐药EGFRm晚期NSCLC患者的II期研究（WU-KONG9）

汇报人：胡洁（复旦大学附属中山医院）

Survival Impact of Immunotherapy(IO) after Chemo-failure in EGFR-mutated NSCLC：A post-hoc analysis of the Orient-31 trial
EGFR突变NSCLC化疗失败后免疫治疗（IO）对生存的影响：Orient-31试验的事后分析

汇报人：李子明（上海交通大学医学院附属胸科医院）

PET/Fluorescence Dual-Modal Tracing for Targeted Inhibition of RRM2 to Overcome Osimertinib Resistance in Lung Cancer
PET/荧光双模示踪靶向抑制RRM2以克服肺癌奥希替尼耐药

汇报人：Jinyu Zhu（北京）

Optimizing Treatment Strategies for EGFR 21L858R mutation Non-Small Cell Lung Cancer with Brain Metastases: A Real-world Analysis of First-Line EGFR-TKI Efficacy

优化EGFR 21L858R突变NSCLC伴脑转移的治疗策略：一线EGFR-TKI疗效的真实世界分析

汇报人：陈丽昆 (中山大学肿瘤防治中心)

Real-World Post-progression Analysis of First-Line Osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH Study)

中国EGFR突变晚期NSCLC一线奥希替尼治疗后进展的真实世界分析（FLOURISH研究）

汇报人：周建娅（浙江大学医学院附属第一医院）

Firmonertinib plus anlotinib for first-line treatment of advanced EGFR L858R mutated non-small cell lung cancer

伏美替尼联合安罗替尼一线治疗晚期EGFR L858R突变NSCLC

汇报人：周进（四川省肿瘤医院）

EGFR-mutant Advanced NSCLC Patients Continuously Benefit From Aumolertinib as Post Secone-Line Treatment

EGFR突变晚期NSCLC患者在二线治疗后持续受益于阿美替尼

汇报人：刘智华 (江西省肿瘤医院)

Final Overall Survival and Long-term Safety Outcomes of Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 (METex14) Mutation: An Update from a Phase 3b Study

赛沃替尼治疗MET外显子14（METex14）突变的局部晚期或转移性NSCLC患者的最终总生存期和长期安全性结局：一项3b期研究的更新

汇报人：虞永峰（上海市胸科医院）

Efficacy of subsequent therapy following the progression of crizotinib in advanced ROS1+ NSCLC in real word setting

真实世界中，克唑替尼治疗晚期ROS1+NSCLC进展后的后续治疗疗效

汇报人：Zihua Zou（北京）

Intracranial efficacy of crizotinib in advanced ROS1+NSCLC in real world setting

真实世界中，克唑替尼在晚期ROS1+NSCLC中的颅内疗效

汇报人：Zihua Zou（北京）

A web-based calculator to Predict the Occurrence of Severe Immune-Related Adverse Events in Non-Small Cell Lung Cancer: Based on a Prospective Study

用于预测NSCLC患者发生严重免疫相关不良事件的网络计算器：基于一项前瞻性研究

汇报人：Peng Song（北京）

Clinical Application and Potential Benefits of En-bloc Biopsy Based on Minimally Invasive Surgery for Advanced Lung Cancer

基于微创手术的En-bloc活检在晚期肺癌中的临床应用和潜在益处

汇报人：Jianfu Li（广州）

An Open-Label, Single-Arm, Phase Ib Exploratory Study to Evaluate the Safety and Efficacy of Golidocitinib in Combination with Anti-PD-1 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1 Containing Regimens

一项开放标签、单臂、Ib期探索性研究，评估戈利昔替尼联合抗PD-1药物在接受含抗PD-1方案治疗的局部晚期或转移性NSCLC患者中的安全性和疗效

汇报人：钟华 (上海交通大学医学院附属胸科医院)

High-Dose Aumolertinib as First-Line Treatment in Advanced NSCLC Patients harboring EGFR 21L858R Mutation (AHEAD)

高剂量阿美替尼作为携带EGFR 21L858R突变的晚期NSCLC患者的一线治疗（AHEAD）

汇报人：林立平（广州医科大学附属番禺中心医院）

Deep learning-based prediction of lung cancer visceral pleural invasion during thoracoscopic surgery: A multicenter study

基于深度学习的胸腔镜手术期间肺癌内脏胸膜浸润的预测：一项多中心研究

汇报人：Hao Xu（北京）

Identification of the Lymph Node Metastasis Atlas and Optimal Lymph Node Dissection Strategy in Patients with Resectable Lung Invasive Mucinous Adenocarcinoma: A Real-World Multicentre Study

可切除肺浸润性粘液腺癌患者淋巴结转移图谱的识别和最佳淋巴结清扫策略：一项真实世界多中心研究

汇报人：赫捷 (中国医学科学院肿瘤医院)

Microwave Ablation Versus Lobectomy for Ground-Glass Opacity Nodules in the Hilar Region: A Multicenter Prospective Real-World Study on Efficacy and Safety

微波消融 vs 肺叶切除术治疗肺门区磨玻璃样阴影结节的疗效和安全性，多中心前瞻性真实世界研究

汇报人：Wangrui Liu（上海）

Perioperative Immunotherapy Treatment in Resectable Non-Small Cell Lung Cancer with KRAS Mutation: A Real-World Study (Peri-R-01)

KRAS突变的可切除NSCLC围手术期免疫治疗：一项真实世界研究（Peri-R-01）

汇报人：钟华 (上海交通大学附属胸科医院)

Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A NSCLC with High risk factors and EGFR-sensitizing Mutations (APPOINT)

阿美替尼作为辅助治疗在具有高危因素和EGFR敏感突变的可切除IA期NSCLC中的疗效和安全性（APPOINT）

汇报人：韩宝惠（上海交通大学医学院附属胸科医院）

Comparative investigation of neoadjuvant chemoimmunotherapy versus perioperative (chemo)immunotherapy in resectable non–small cell lung cancer: A real-world retrospective study

新辅助化疗免疫治疗与围手术期（化疗）免疫治疗在可切除NSCLC中的比较研究：一项真实世界回顾性研究

汇报人：Sini N. Li (杭州)

Real-world Adjuvant Treatment Patterns in Chinese Patients with Resected Stages I to III EGFR-mutated NSCLC: A Multi-center Observational Study (ADDRESS, CATO-2001)

已切除的I-III期EGFR突变NSCLC中国患者的真实世界辅助治疗模式：一项多中心观察性研究（ADDRESS，CATO-2001）

汇报人：梁文华（广州医科大学附属第一医院）

Survival after wedge resection, segmentectomy and lobectomy for clinical stage IA non-small cell lung cancer: a network meta-analysis and systematic review

临床IA期NSCLC楔形切除术、肺段切除术和肺叶切除术后的生存率：一项网络荟萃分析和系统评价

汇报人：沈建飞（浙江省台州医院）

A Real world study of Adjuvant furmonertinib in patients with stage IA-IIIA EGFR-mutant non-small-cell lung cancer

伏美替尼辅助治疗IA-IIIA期EGFR突变NSCLC患者的真实世界研究

汇报人：Jiayue Ye（杭州）

The Clinical Response and Safety of Neoadjuvant Alectinib in Lung Adenocarcinoma with ALK Rearrangement: A Two-Center Retrospective Study

阿来替尼新辅助治疗伴ALK重排的肺腺癌的临床应答和安全性：一项双中心回顾性研究

汇报人：Liang Shi（北京）

Adjuvant Aumolertinib for Resected EGFR-Mutated Stage IA2-ⅢA Non-Small-Cell Lung Cancer: Updated Results From A multiple-center real-world experience

阿美替尼辅助治疗已切除EGFR突变IA2-ⅢA期NSCLC：多中心真实世界经验的更新结果

汇报人：Qingyi Zhang（杭州）

MRD Evaluation of Aumolertinib in EGFR Mutation-positive stage IB and stage IA2-3 NSCLC After Complete Surgical Resection: A Multicenter, Single-arm, Open-lable Study

阿美替尼在EGFR突变阳性IB期和IA2-3期NSCLC完全手术切除后的MRD评估：一项多中心、单臂、开放标签研究

汇报人：程超 (中山大学附属第一医院)

Perioperative Adebrelimab Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Multicenter, Phase II Trial

围手术期阿得贝利单抗联合化疗治疗携带EGFR突变的可切除NSCLC：一项多中心、II期试验

汇报人：Gebang Wang（沈阳）

Phase II Clinical Study of Adebrelimab Combined with Carboplatin, Albumin-Bound Paclitaxel, and Recaticimab in Perioperative Treatment of Resectable NSCLC

阿得贝利单抗联合卡铂、白蛋白结合型紫杉醇和瑞卡西单抗围手术期治疗可切除NSCLC的II期临床研究

汇报人：Jinghui Wang（北京）

Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer (NEOLORA)

洛拉替尼作为IB-IIIB期ALK重排NSCLC的新辅助治疗（NEOLORA）

汇报人：杨帆（北京大学人民医院）

Efficacy and Safety of Induction Chemo-Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Multicenter Retrospective Study

诱导化疗-免疫治疗在不可切除的III期NSCLC中的疗效和安全性：一项真实世界多中心回顾性研究

汇报人：Wenlu Chen（太原）

Durvalumab after Definitive Chemoradiation (dCRT) in Non-small cell lung cancer (NSCLC) patients with Actionable Driver Mutations

在具有可靶向驱动突变的NSCLC患者中，根治性放化疗（dCRT）后使用度伐利尤单抗

汇报人：Jason C S（中国香港九龙）

EGFR-TKI Combined with Chemotherapy versus EGFR-TKI Alone for locally advanced EGFR-mutant NSCLC: A Real-World Study

EGFR-TKI联合化疗与单用EGFR-TKI治疗局部晚期EGFR突变NSCLC的真实世界研究

汇报人：Yu Jiang（广州）

Four-Year Outcomes with Perioperative Toripalimab plus Chemotherapy in Resectable Stage III Non-Small Cell Lung Cancer (NeoTAP01 Study)

围手术期特瑞普利单抗联合化疗治疗可切除的III期NSCLC的4年结果（NeoTAP01研究）

汇报人：Yuheng Zhou（广州）

Recurrence in Patients with Non–Small Cell Lung Cancer Achieving Pathological Complete Response after Neoadjuvant Treatment

新辅助治疗后达到病理完全缓解的NSCLC患者的复发情况

汇报人：Yuechun Lin（广州）

Refining Central Lung Cancer Surgery: Uniportal Video-Assisted Thoracic Surgery with Three-Dimensional Vascular Mapping After Neoadjuvant Chemoimmunotherapy

改良中央型肺癌手术：新辅助化疗免疫治疗后的单孔胸腔镜手术结合三维血管成像

汇报人：罗志林（重庆医科大学附属第三医院）

Safety and Necessity of Mediastinal Lymph Nodes Dissection Omission Following Nodal Clearance with Neoadjuvant Immunochemotherapy in cN0/N1 Non-Small Cell Lung Cancer

新辅助免疫化疗后淋巴结清除情况下，cN0/N1 NSCLC患者不进行纵隔淋巴结清扫的安全性和必要性

汇报人：Yuheng Zhou（广州）

Prognostic Impacts of Skip Metastasis in N2a and N2b Subgroups in Non-Small Cell Lung Cancer：Insights from a Large Cohort

NSCLC N2a和N2b亚组跳跃转移的预后影响：来自大型队列的见解

汇报人：Shenhua Liang（广州）

Type VII Collagen Enhances Matrix Viscoelasticity and Modulates Immune Response in Advanced Lung Adenocarcinoma

VII型胶原增强晚期肺腺癌基质粘弹性和调节免疫反应

汇报人：Pengxu Kong (杭州)

125I particles implantation is an effective therapy for oligo-progression during immunotherapy.

125 I粒子植入是治疗免疫治疗期间寡进展的有效方法

汇报人：Xiao Fu (西安)

Surgical and Pathology Outcome of a Randomized, Phase II Trial of EGFR TKI with Primary Tumor Resection for EGFR-Mutant Metastatic NSCLC Patients: Feasibility Evaluation

EGFR TKI联合原发性肿瘤切除术治疗EGFR突变转移性NSCLC患者的随机、II期试验的手术和病理学结果：可行性评价

汇报人：陈沛兴（中国台湾大学医学院附设医院新竹台大分院）

Serial monitoring of cerebrospinal fluid in lung cancer patients with brain metastases via the ommaya reservoir as a predictive indicator of therapeutic efficacy and clinical prognosis

通过Ommaya囊对肺癌脑转移患者脑脊液进行连续监测，作为治疗效果和临床预后的预测指标

汇报人：方申存 (南京市胸科医院)

Pan-cancer analyses reveal tissue-type-specific intracellular bacteria in lung metastatic cancer

泛癌分析揭示了肺转移癌中的组织类型特异性细胞内细菌

汇报人：Haiming Chen（福州）

Association of Gut Microbiome with Radiotherapy Efficacy in Lung Cancer Patients with Brain Metastases

肺癌脑转移患者肠道微生物组与放射治疗疗效的关系

汇报人：夏铀铀 (连云港市第一人民医院)

Innovative Portable Breathomic Device For Early Non-Invasive Differentiation Of Benign And Malignant Lung Nodules

创新便携式呼吸装置，用于早期无创鉴别良性和恶性肺结节

汇报人：梁恒瑞 (广州医科大学附属第一医院)

Association Between Digestive System Diseases and Lung Cancer Risk: A Comprehensive Evaluation based on UK Biobank

消化系统疾病与肺癌风险之间的关联：基于英国生物样本库的综合评估

汇报人：Yi Feng（广州）

Association Between Serum Branched-Chain Amino Acids and Cancer Risk: Findings from a Prospective Cohort Study in the UK Biobank

血清支链氨基酸与癌症风险之间的关联：来自英国生物样本库前瞻性队列研究的结果

汇报人：Yi Feng（广州）

A multicenter exhaled breath metabolomics lung cancer screening model based on PTR-TOF MS

基于PTR-TOF MS的多中心呼气代谢组学肺癌筛查模型

汇报人：Chen Huang（成都）

Preliminary results of LC-SHIELD study (Lung Cancer Screening in HIgh risk non-smokErs with artificial inteLligence Device)

LC-SHIELD研究的初步结果（使用人工智能设备对高危非吸烟者进行肺癌筛查）

汇报人：Siu Ching M. Li (中国香港沙田)

Dynamic Machine Learning for Early Lung Cancer Identification Using Longitudinal Clinical and Laboratory Data

使用纵向临床和实验室数据进行早期肺癌识别的动态机器学习

汇报人：叶文君 (广州医科大学附属第一医院)

Study on screening and diagnosis model of smokers based on PTR-TOF-MS

基于PTR-TOF-MS的吸烟者筛查诊断模型研究

汇报人：Chen Huang（成都）

CT-based intratumoral and peritumoral radiometric characteristics accurately predict the risk of distant metastasis in small cell lung cancer

基于CT的瘤内和瘤周放射学特征准确预测SCLC远处转移的风险

汇报人：王苒（安徽医科大学第一附属医院）

Phase 2 study of the efficacy and safety of BNT327/PM8002 plus systemic chemotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC)

BNT327/PM8002联合全身化疗作为广泛期小细胞肺癌（ES-SCLC）一线治疗的有效性和安全性的II期研究

汇报人：程颖（吉林省肿瘤医院）

Prognostic markers and Molecular Insights: Navigating SCLC with Liver Metastasis

预后标志物与分子洞察：探索伴肝转移的SCLC

汇报人：Jing Ding (成都)

Real-world outcomes in extensive-stage small cell lung cancer treated with first-line serplulimab: The nationwide observational ASTRUM-005R study

一线斯鲁利单抗治疗ES-SCLC的真实世界结局：全国观察性ASTRUM-005R研究

汇报人：Lin Wu（长沙）

Final overall survival (OS) of surufatinib plus PD-1/PD-L1 antibodies as maintenance therapy following first line (1L) platinum-based chemotherapy (Chemo) plus PD-1/PD-L1 antibodies in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

ES-SCLC患者接受一线含铂化疗+PD-1/PD-L1抗体后，索凡替尼+PD-1/PD-L1抗体作为维持治疗的最终总生存期（OS）

汇报人：胡毅（中国人民解放军总医院）

Impact of Induction Chemotherapy Cycles on the Efficacy of First-Line Atezolizumab Combined with Chemotherapy in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

诱导化疗周期对一线阿替利珠单抗联合化疗治疗ES-SCLC疗效的影响

汇报人：Mengxing You（北京）

Impact of Prophylactic Cranial Irradiation on Survival in Extensive-Stage Small Cell Lung Cancer Receiving First-Line Chemoimmunotherapy: A Propensity Score-Matched Study

预防性颅脑照射对接受一线化疗免疫治疗的ES-SCLC患者生存的影响：一项倾向评分匹配研究

汇报人：范云（浙江省肿瘤医院）

Lysine-specific Demethylase 1A (LSD1) inhibition attenuates phenotypic transition and delays the tumor relapse to radioimmunotherapy in small cell lung cancer

赖氨酸特异性去甲基化酶1A（LSD1）抑制可减弱SCLC的表型转化并延缓放射免疫治疗的肿瘤复发

汇报人：Hui Wang（成都）

Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer

小细胞外囊泡miRNAs作为ES-SCLC免疫化疗疗效的预测生物标志物

汇报人：Wei Zhang（上海）

The Prognostic Analysis and Model Establishment of Central and Peripheral Small Cell Lung Cancer

中央型和周围型SCLC的预后分析及模型建立

汇报人：Xiao Fu (西安)

Intracranial efficacy of YL201, a novel B7-H3-targeting antibody-drug conjugate (ADC), in patients (pts) with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)

YL201（一种新型B7-H3靶向抗体药物偶联物（ADC））在SCLC和NSCLC患者中的颅内疗效

汇报人：赵洪云（中山大学肿瘤防治中心）

A single-arm, open-label, prospective, single-center clinical study on the treatment of patinum-resistant relapse small cell lung cancer with nab-paclitaxel combined with apatinib

白蛋白结合型紫杉醇联合阿帕替尼治疗铂耐药复发SCLC的单臂、开放标签、前瞻性、单中心临床研究

汇报人：杨雪（北京大学肿瘤医院）

Updated phase II efficacy and safety results of BNT327/PM8002 combined with paclitaxel as second-line (2L) therapy in small cell lung cancer (SCLC)

BNT327/PM8002联合紫杉醇作为SCLC二线治疗的II期疗效和安全性结果更新

汇报人：程颖（吉林省肿瘤医院）

Safety and effectiveness of adebrelimab as second- or later-line treatment in extensive-stage small-cell lung cancer: a prospective, real-world study

阿得贝利单抗作为ES-SCLC二线或二线后治疗的安全性和有效性：一项前瞻性真实世界研究

汇报人：Xiaoli Liu（青岛）